Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 10/20 | 0.60 |
| ▸ | CNR2 | P34972 | 8/20 | 0.57 |
| ▸ | CDC25A | P30304 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8959906 | 0.88 | CNR2 (0.57) | CNR1CNR2TSHRALDH1A1LMNA | |
| SCHEMBL8959968 | 0.85 | CNR2 (0.67) | CNR1CNR2CDC25ACREBBP | |
| SCHEMBL8959732 | 0.85 | CNR2 (0.67) | CNR1CNR2CDC25ACREBBP | |
| SCHEMBL8959987 | 0.85 | CNR2 (0.67) | CNR1CNR2CDC25ACREBBP | |
| SCHEMBL8959748 | 0.85 | CNR2 (0.67) | CNR1CNR2CDC25ACREBBP | |
| SCHEMBL8959985 | 0.85 | CNR2 (0.67) | CNR1CNR2CDC25ACREBBP | |
| SCHEMBL8959839 | 0.85 | CNR2 (0.67) | CNR1CNR2CDC25ACREBBP | |
| SCHEMBL9247864 | 0.85 | CNR2 (0.67) | CNR1CNR2CDC25ACREBBP | |
| SCHEMBL286791 | 0.83 | CNR2 (0.72) | CNR1CNR2CDC25A | |
| SCHEMBL9543327 | 0.83 | CNR2 (0.66) | CNR1CNR2TSHRALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5530019-A | FOR TREATMENT OF PROSTATE GLAND DISORDERS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-06-25 | — | — | US | disclosed |